Rocket Lab Soars on $90M Space Force Win, But DeepValue Flags Persistent Execution Risks

What happened

Rocket Lab stock surged after the company announced a new $90 million contract with the U.S. Space Force and a successful satellite launch. While the contract adds to an already robust $2.2B backlog, the latest DeepValue report cautions that only 36% of that backlog is expected to be recognized within 12 months, with delivery slippage on the MDA contract and potential liquidated damages. The company remains cash-flow negative, funding operations and Neutron development through an ATM equity program that raised $445.6 million net in Q1 2026, further diluting shareholders. The stock price of $125 implies aggressive backlog conversion and that Neutron's first launch (targeted for Q4 2026) stays on track, yet the January tank qualification failure and ongoing supply-chain issues inject significant uncertainty. Positive news does not alter the fundamental risk-reward skew, which remains negative given crowded positioning and valuation with no margin of safety.

Implication

The $90M Space Force award boosts backlog confidence and validates defense demand, but Rocket Lab's path to profitability still hinges on flawless execution: converting backlog at higher margins, avoiding MDA liquidated damages, and delivering Neutron on schedule. Until Q2 2026 results prove revenue and margin durability (guided $225M-$240M, 33%-35% gross margin) and backlog 12-month recognition improves from ~36%, valuation at $125 with a $72.6B market cap offers limited upside. The reliance on equity funding and insider selling overhang (clustered sales by CEO, CFO, COO in March 2026) further pressure the stock. Investors should wait for Q2 earnings and clear Neutron progress before considering entry below DeepValue's attractive entry of $95.

Thesis delta

The $90M Space Force win and successful launch momentarily bolster the bull narrative around defense demand and launch cadence, but they do not mitigate the core risks of backlog conversion, MDA slippage, and Neutron schedule uncertainty. The thesis shifts slightly more positive on near-term demand signals, yet the overwhelming evidence of execution risk, equity dilution, and crowded market sentiment keeps the overall assessment bearish. Our POTENTIAL SELL rating stands until Q2 results evidence conversion quality and margin stability.